A point mutation associated with a severe phenotype of neurofibromatosis 2

被引:11
作者
MacCollin, M
Braverman, N
Viskochil, D
Ruttledge, M
Davis, K
Ojemann, R
Gusella, J
Parry, DM
机构
[1] MASSACHUSETTS GEN HOSP,DEPT NEUROL,BOSTON,MA 02114
[2] MASSACHUSETTS GEN HOSP,DEPT NEUROSURG,BOSTON,MA 02114
[3] MASSACHUSETTS GEN HOSP,NEUROGENET UNIT,BOSTON,MA 02114
[4] JOHNS HOPKINS CTR MED GENET,BALTIMORE,MD
[5] NCI,GENET EPIDEMIOL BRANCH,BETHESDA,MD 20892
[6] UNIV UTAH,DEPT PEDIAT,SALT LAKE CITY,UT
[7] MCGILL UNIV,CTR RES NEUROSCI,MONTREAL,PQ H3A 2T5,CANADA
关键词
D O I
10.1002/ana.410400313
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Neurofibromatosis 2 (NF2) is an autosomal dominant disease characterized by bilateral vestibular schwannomas and other nonmalignant tumors of the brain, spinal cord, and peripheral nerves. Although the average age of onset of NF2 is 20 years, some individuals may become symptomatic in childhood. We studied 5 unrelated NF2 patients who became symptomatic before age 13. All 5 had multiple tumors in addition to vestibular schwannoma, and none had a positive family history. Sequence analysis of the NF2 gene revealed identical nonsense mutation of exon 6 in 3 patients. Because this mutation destroys a restriction enzyme recognition site, genomic DNA from the 2 other children was directly tested for this change and identical alterations were detected. Although the work of our laboratory and others has not, in general, detected identical mutations in unrelated patients, this mutation seems to occur particularly frequently in the pediatric population and thus may be associated with an especially severe phenotype. Restriction analysis in children with NF2 may be a cost effective way of identifying their mutation. Further work is needed to characterize the effects of this change on the NF2 protein product and its relationship to this severe phenotype.
引用
收藏
页码:440 / 445
页数:6
相关论文
共 29 条
[1]  
Andermann A. A., 1994, American Journal of Human Genetics, V55, pA209
[2]   SPECTRUM OF GERMLINE MUTATIONS IN THE RB1 GENE - A STUDY OF 232 PATIENTS WITH HEREDITARY AND NON HEREDITARY RETINOBLASTOMA [J].
BLANQUET, V ;
TURLEAU, C ;
GROSSMORAND, MS ;
BEAUFORT, CS ;
DOZ, F ;
BESMOND, C .
HUMAN MOLECULAR GENETICS, 1995, 4 (03) :383-388
[3]   GERMLINE MUTATIONS IN THE NEUROFIBROMATOSIS TYPE-2 TUMOR-SUPPRESSOR GENE [J].
BOURN, D ;
CARTER, SA ;
MASON, S ;
EVANS, DGR ;
STRACHAN, T .
HUMAN MOLECULAR GENETICS, 1994, 3 (05) :813-816
[4]  
BOURN D, 1994, AM J HUM GENET, V55, P69
[5]   VISUAL IMPAIRMENT IN PATIENTS WITH NEUROFIBROMATOSIS-2 [J].
BOUZAS, EA ;
PARRY, DM ;
ELDRIDGE, R ;
KAISERKUPFER, MI .
NEUROLOGY, 1993, 43 (03) :622-623
[6]  
Carey J C, 1979, Birth Defects Orig Artic Ser, V15, P271
[7]   GERMLINE MUTATIONS IN THE VONHIPPEL-LINDAU DISEASE TUMOR-SUPPRESSOR GENE - CORRELATIONS WITH PHENOTYPE [J].
CHEN, F ;
KISHIDA, T ;
YAO, M ;
HUSTAD, T ;
GLAVAC, D ;
DEAN, M ;
GNARRA, JR ;
ORCUTT, ML ;
DUH, FM ;
GLENN, G ;
GREEN, J ;
HSIA, YE ;
LAMIELL, J ;
LI, H ;
WEI, MH ;
SCHMIDT, L ;
TORY, K ;
KUZMIN, I ;
STACKHOUSE, T ;
LATIF, F ;
LINEHAN, WM ;
LERMAN, M ;
ZBAR, B .
HUMAN MUTATION, 1995, 5 (01) :66-75
[8]  
CROSSEY PA, 1994, HUM MOL GENET, V3, P1303
[9]  
EASTON DF, 1993, AM J HUM GENET, V53, P305
[10]   DIAGNOSTIC ISSUES IN A FAMILY WITH LATE-ONSET TYPE-2 NEUROFIBROMATOSIS [J].
EVANS, DGR ;
BOURN, D ;
WALLACE, A ;
RAMSDEN, RT ;
MITCHELL, JD ;
STRACHAN, T .
JOURNAL OF MEDICAL GENETICS, 1995, 32 (06) :470-474